Assessing Electronic Cigarette Nicotine Flux

Overview

The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Participant)
  • Study Primary Completion Date: April 2022

Interventions

  • Other: ECIG Lab Session, 30 watts
    • During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Arms, Groups and Cohorts

  • Active Comparator: Cigarette Smokers: 0 mg/ml nicotine concentration
    • ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
  • Experimental: Cigarette Smokers: 4 mg/ml nicotine concentration
    • ECIG Lab Session, 30 watts, 4 mg/ml nicotine concentration During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
  • Experimental: Cigarette Smokers: 15 mg/ml nicotine concentration
    • ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
  • Experimental: Cigarette Smokers: 30 mg/ml nicotine concentration
    • ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Clinical Trial Outcome Measures

Primary Measures

  • Plasma Nicotine Concentration
    • Time Frame: Approximately 205 minutes
    • Change in plasma nicotine concentration Blood will be taken 5 times in each session to examine changes from baseline (approx. 90 minutes) to immediately follow a ten-puff bout (approx. 100, 120, and 190 minutes), and immediately after the cigarette challenge paradigm (approx. 205 minutes).
  • Cigarette Challenge Paradigm
    • Time Frame: This task will occur at approximiately 200 minutes until 205 minutes
    • The cigarette challenge paradigm is a procedure in which participants will be given a 5 minute time period in which they are allowed to smoke their own brand cigarette as much or as little as they want. Study staff will provide the participant with their own brand cigarettes, a lighter, and an ash tray. Latency to start the first puff and number of puffs will be recorded.

Secondary Measures

  • Change in heart rate
    • Time Frame: Baseline to 255 minutes
    • Change in heart rate, measured in beats per minute.
  • Puff volume
    • Time Frame: Puff volume will be measured during the approximately 5-minute, 10-puff use bout.
    • The volume of each puff, in ml.
  • Puff duration
    • Time Frame: Puff duration will be measured during the approximately 5-minute, 10-puff use bout.
    • The duration of each puff, measured in second.
  • Inter puff interval
    • Time Frame: Inter puff interval will be measured during the approximately 5-minute, 10-puff use bout.
    • The time between each puff, in seconds.
  • Flow rate
    • Time Frame: Flow rate will be measured during the approximately 5-minute, 10-puff use bout.
    • The rate of air flow during each puff, in ml/second.
  • Direct Effects of Vaping Questionnaire
    • Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes.
    • This measure is related to the effects of vaping (10 questions, each scored from 0 – 100).
  • Direct Effects of Nicotine Questionnaire
    • Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes.
    • This measure is related to the side effects of nicotine (10 questions, each scored from 0 – 100).
  • Hughes-Hatsukami Questionnaire
    • Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes.
    • This measure is related to nicotine abstinence symptoms (11 questions, each scored from 0 – 100).
  • General Labeled Magnitude Scale
    • Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes.
    • This measure is related to perceptions of electronic cigarette effects (3 questions, each scored from 0 – 100).
  • Labeled Hedonic Scale
    • Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes.
    • This measure is related to perceptions of electronic cigarette effects (4 questions, each scored from 0 – 100).

Participating in This Clinical Trial

Inclusion Criteria

  • healthy (determined by self-report)
  • between the ages of 18-55
  • willing to provide informed consent
  • able to attend the lab and abstain from tobacco/nicotine as required and must agree to use designated products according to study protocol

Exclusion Criteria

• Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.

Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Virginia Commonwealth University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alison Breland, PhD, Study Director, Virginia Commonwealth University
  • Overall Contact(s)
    • Alison Breland, PhD, (804) 628-2300, abbrelan@vcu.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.